Article

Exchange Maps Out Plan for Next Year

The state Health Benefit Exchange board finalized and submitted its request to federal officials for a $196 million Level 1.2 establishment grant -- essentially mapping out the exchange's plans over the next year.

Exchange executive director Peter Lee made the announcement at the board's July 19 meeting in Oakland.

Read the full story: http://tinyurl.com/d4po8zl

Source: California Healthline

Related Videos
ATS 2025
Bridgette J. Picou, LVN, ACLPN, The Well Project
John Barkett, MBA
1 expert in this video
Dr Gerard Criner
Emma Achola-Kothari, PhD
Dr Margrit Wiesendanger
Related Content
Joe Biden | Image credit: ABC News
May 23rd 2025

News Reports on Biden’s Prostate Cancer Reflect Controversy, Limits of PSA Testing

Mary Caffrey
Following former President Joe Biden's diagnosis with metastatic prostate cancer, news coverage has focused on his lack of prostate-specific antigen (PSA) screening over the past decade.
Managed Care Cast
May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville
Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Based on western blot testing, patients who received gene therapy at 2 years old showed a mean dystrophin expression of 93.87% of normal. | Image Credit: Treecha - stock.adobe.com
May 23rd 2025

DMD Gene Therapy Shows Efficacy, Safety in Patients Treated at 2 Years Old

Rose McNulty
Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
May 23rd 2025

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

Jared Kaltwasser
Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.
Light sensitivity is a potential symptom of myasthenia gravis that has historically been under-researched, according to study authors. | Image credit: lexiconimages - stock.adobe.com
May 23rd 2025

Light Sensitivity Linked With Lower Quality of Life in Myasthenia Gravis

Jared Kaltwasser
New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the need for targeted treatment strategies.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo